Latigo Biotherapeutics, Inc. (LTGO)

Latigo Biotherapeutics, Inc. is trading at $16.57, up 1.41% on the session. The 50 day average sits at $19.53 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 48.4, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $16.19 with resistance near $20.49, so that band frames the current range. Average daily movement is roughly $1.42, or about 8.5% of the share price, which is what any stop placement has to allow for. The overall health score of 37 out of 100 combines a trend score of 32, momentum of 54 and a risk score of 22.

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.